917 related articles for article (PubMed ID: 8035346)
1. Effects of alatriopril, a mixed inhibitor of atriopeptidase and angiotensin I-converting enzyme, on cardiac hypertrophy and hormonal responses in rats with myocardial infarction. Comparison with captopril.
Bralet J; Marie C; Mossiat C; Lecomte JM; Gros C; Schwartz JC
J Pharmacol Exp Ther; 1994 Jul; 270(1):8-14. PubMed ID: 8035346
[TBL] [Abstract][Full Text] [Related]
2. [Systemic and regional hemodynamic effects of a new angiotensin converting enzyme and neutral endopeptidase mixed inhibitor, alatriopril, in the dog].
Richard V; Lecomte JM; Thuillez C
Arch Mal Coeur Vaiss; 1993 Aug; 86(8):1275-9. PubMed ID: 8129543
[TBL] [Abstract][Full Text] [Related]
3. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
Gonzalez W; Beslot F; Laboulandine I; Fournié-Zaluski MC; Roques BP; Michel JB
J Pharmacol Exp Ther; 1996 Aug; 278(2):573-81. PubMed ID: 8768706
[TBL] [Abstract][Full Text] [Related]
5. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure.
Seymour AA; Asaad MM; Lanoce VM; Langenbacher KM; Fennell SA; Rogers WL
J Pharmacol Exp Ther; 1993 Aug; 266(2):872-83. PubMed ID: 8394922
[TBL] [Abstract][Full Text] [Related]
6. Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction.
Westendorp B; Schoemaker RG; Buikema H; de Zeeuw D; van Veldhuisen DJ; van Gilst WH
J Renin Angiotensin Aldosterone Syst; 2004 Mar; 5(1):27-32. PubMed ID: 15136971
[TBL] [Abstract][Full Text] [Related]
7. Effect of long-term therapy with fasidotril, a mixed inhibitor of neprilysin and angiotensin-converting enzyme (ACE), on survival of rats after myocardial infarction.
Marie C; Mossiat C; Gros C; Schwartz JC; Lecomte JM; Bralet J
Cardiovasc Res; 1999 Mar; 41(3):544-53. PubMed ID: 10435026
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.
Lassila M; Davis BJ; Allen TJ; Burrell LM; Cooper ME; Cao Z
Clin Sci (Lond); 2003 Apr; 104(4):341-7. PubMed ID: 12653675
[TBL] [Abstract][Full Text] [Related]
9. Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation.
Maki T; Nasa Y; Tanonaka K; Takahashi M; Takeo S
J Pharmacol Exp Ther; 2003 Apr; 305(1):97-105. PubMed ID: 12649357
[TBL] [Abstract][Full Text] [Related]
10. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin I converting enzyme inhibitors and cardiac remodeling.
van Krimpen C; Schoemaker RG; Cleutjens JP; Smits JF; Struyker-Boudier HA; Bosman FT; Daemen MJ
Basic Res Cardiol; 1991; 86 Suppl 1():149-55. PubMed ID: 1827981
[TBL] [Abstract][Full Text] [Related]
12. Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure.
Rademaker MT; Charles CJ; Nicholls MG; Richards AM
Clin Sci (Lond); 2008 May; 114(10):635-42. PubMed ID: 18052934
[TBL] [Abstract][Full Text] [Related]
13. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
[TBL] [Abstract][Full Text] [Related]
14. Marked difference between angiotensin-converting enzyme and neutral endopeptidase inhibition in vivo by a dual inhibitor of both enzymes.
Anastasopoulos F; Leung R; Kladis A; James GM; Briscoe TA; Gorski TP; Campbell DJ
J Pharmacol Exp Ther; 1998 Mar; 284(3):799-805. PubMed ID: 9495836
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of either angiotensin-converting enzyme or neutral endopeptidase induces both enzymes.
Helin K; Tikkanen I; Hohenthal U; Fyhrquist F
Eur J Pharmacol; 1994 Oct; 264(2):135-41. PubMed ID: 7851475
[TBL] [Abstract][Full Text] [Related]
16. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril.
Gros C; Noël N; Souque A; Schwartz JC; Danvy D; Plaquevent JC; Duhamel L; Duhamel P; Lecomte JM; Bralet J
Proc Natl Acad Sci U S A; 1991 May; 88(10):4210-4. PubMed ID: 1851998
[TBL] [Abstract][Full Text] [Related]
17. Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenopril.
Westendorp B; Schoemaker RG; van Gilst WH; van Veldhuisen DJ; Buikema H
Eur J Pharmacol; 2005 Dec; 527(1-3):141-9. PubMed ID: 16310764
[TBL] [Abstract][Full Text] [Related]
18. Role of neutral endopeptidase 24.11 in AV fistular rat model of heart failure.
Wegner M; Hirth-Dietrich C; Stasch JP
Cardiovasc Res; 1996 Jun; 31(6):891-8. PubMed ID: 8759244
[TBL] [Abstract][Full Text] [Related]
19. Hemodynamic effects of acute and chronic treatment with aladotril, a mixed inhibitor of neutral endopeptidase and angiotensin I-converting enzyme, in conscious rats with myocardial infarction.
Marie C; Mossiat C; Lecomte JM; Schwartz JC; Bralet J
J Pharmacol Exp Ther; 1995 Dec; 275(3):1324-31. PubMed ID: 8531099
[TBL] [Abstract][Full Text] [Related]
20. Regulation of insulin-like growth factor-1 by the renin-angiotensin system during regression of cardiac eccentric hypertrophy through angiotensin-converting enzyme inhibitor and AT1 antagonist.
Haddad GE; Blackwell K; Bikhazi A
Can J Physiol Pharmacol; 2003 Feb; 81(2):142-9. PubMed ID: 12710528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
